{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:00:57Z","timestamp":1761742857458},"reference-count":51,"publisher":"Japanese Pharmacological Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2006]]},"DOI":"10.1254\/jphs.fp0060673","type":"journal-article","created":{"date-parts":[[2006,10,19]],"date-time":"2006-10-19T05:46:44Z","timestamp":1161236804000},"page":"213-219","source":"Crossref","is-referenced-by-count":18,"title":["The Elucidation of the Mechanism of Weight Gain and Glucose Tolerance Abnormalities Induced by Chlorpromazine"],"prefix":"10.1254","volume":"102","author":[{"given":"Takahiro","family":"Amamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Kumai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Nakaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimitsu","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"332","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01561635"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Blaceland FJ, Meduna LJ, Vaichulis JA. Delayed action of insulin in schizophrenia. Am J Psychiatry. 1945;102:108–110.","DOI":"10.1176\/ajp.102.1.108"},{"key":"3","unstructured":"3 Langfeldt G. The insulin tolerance test in mental disorders. Acta Psychiatr Scand. 1952;80:189–200."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Compr Psychiatry. 1996;37:68–73.","DOI":"10.1016\/S0010-440X(96)90054-1"},{"key":"5","unstructured":"5 Amdisen A. Drug-produced obesity: experiences with chlorpromazine, perphenazine and clopenthixol. Dan Med Bull. 1964;11:182–189."},{"key":"6","unstructured":"6 Klett CJ, Caffy EMJ. Weight changes during treatment with phenothiazine derivatives. J Neuropsychiatry. 1960;2:102–108."},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.91.259"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med. 2001;111:716–723.","DOI":"10.1016\/S0002-9343(01)01000-2"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002;22:841–852.","DOI":"10.1592\/phco.22.11.841.33629"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0395"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.FMJ04008X2"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Kabinoff GS, Toalson PA, Healey KM, McGuire HC, Hay DP. Metabolic issues with atypical antipsychotics in primary care: dispelling the myths. Prim. Care Companion J Clin Psychiatry. 2003;5:6–14.","DOI":"10.4088\/PCC.v05n0103"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Sporn AL, Bobb AJ, Gogtay N, Stevens H, Greenstein DK, Clasen LS, et al. Hormonal correlates of clozapine-induced weight gain in psychotic children: An exploratory study. J Am Acad Child Adolesc Psychiatry. 2005;44:925–933.","DOI":"10.1097\/01.chi.0000170552.15798.dd"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003;64:598–604.","DOI":"10.4088\/JCP.v64n0516"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Palmiero M, Michele F, Alfonso T, Silvestro LP, Mario M. Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment. J Clin Psychopharmacol. 2002;22:424–426.","DOI":"10.1097\/00004714-200208000-00015"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, Hummer M, et al. Association of olanzapine induce weight gain with an increase in body fat. Am J Psychiatry. 2001;158:1719–1722.","DOI":"10.1176\/appi.ajp.158.10.1719"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Hagg S, Soderberg S, Ahren B, Olsson T, Mjorndal T. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry. 2001;62:843–848.","DOI":"10.4088\/JCP.v62n1102"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Masuzaki H, Ogawa Y, Aizawa-Abe M, Hosoda K, Suga J, Ebihara K, et al. Glucose metabolism and insulin sensitivity in transgenic mice overexpressing leptin with lethal yellow agouti mutation. Diabetes. 1999;48:1615–1622.","DOI":"10.2337\/diabetes.48.8.1615"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Miyanaga F, Ogawa Y, Ebihara K, Hidaka S, Tanaka T, Hayashi S, et al. Leptin as an adjunct of insulin therapy in insulin-deficient diabetes. Diabetologia. 2003;46:1329–1337.","DOI":"10.1007\/s00125-003-1193-6"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.16.1568"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.FMJ04008X5"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.91.125"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry. 1999;156:1686–1696.","DOI":"10.1176\/ajp.156.11.1686"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Thonnard-Neumann E. Phenothiazine and diabetes in hospitalized women. Am J Psychiatry. 1968;124:978–982.","DOI":"10.1176\/ajp.124.7.978"},{"issue":"1","key":"25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF00561782","volume":"11","year":"1977","ISSN":"http:\/\/id.crossref.org\/issn\/0031-6970","issn-type":"print"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Yang B, Brown KK, Chen L, Carrick KM, Clifton LG, McNulty JA, et al. Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insensitization\/lipid lowering in rats. BMC pharmacology. 2004;4:1–9.","DOI":"10.1186\/1471-2210-4-23"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999;60:358–363.","DOI":"10.4088\/JCP.v60n0602"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, et al. Eating disorder and epilepsy in mice lacking 5-HT2C<\/sub> serotonin receptors. Nature. 1995;374:542–546.","DOI":"10.1038\/374542a0"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Inoue A, Nakata Y. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy. J Pharmacol Sci. 2001;86:376–380.","DOI":"10.1254\/jjp.86.376"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.FP0050144"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1210\/er.2003-0011"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.95.9"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Laviola L, Perrini S, Cignarelli A, Natalicchio A, Leonardini A, Stefano FD, et al. Insulin signaling in human visceral and subcutaneous adipose tissue in vivo. Diabetes. 2006;55:952–961.","DOI":"10.2337\/diabetes.55.04.06.db05-1414"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Ebaid GM, Faine LA, Diniz YS, Rodrigues HG, Galhardi CM, Ribas BO, et al. Effects of digitonin on hyperglycaemia and dyslipidemia induced by high-sucrose intake. Food Chem Toxicol. 2006;44:293–299.","DOI":"10.1016\/j.fct.2005.06.015"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Dwyer DS, Bradley RJ, Kablinger AS, Freeman AM. Glucose metabolism relation to schizophrenia and antipsychotic drug treatment. Ann Clin Psychiatry. 2001;13:103–113.","DOI":"10.3109\/10401230109148955"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clin Pharmacol Ther. 1970;11:883–889.","DOI":"10.1002\/cpt1970116883"},{"issue":"1","key":"37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0022-2275(20)42251-5","volume":"32","year":"1991","ISSN":"http:\/\/id.crossref.org\/issn\/0022-2275","issn-type":"print"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Houtia NE, Maziere JC, Maziere C, Auclair M, Gardette J, Polonovski J. Phenothiazine inhibit cholesteryl ester formation in J774 monocyte-like cells. J Clin Chem Clin Biochem. 1988;26:673–678.","DOI":"10.1515\/cclm.1988.26.11.673"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry. 1999;156:312–314.","DOI":"10.1176\/ajp.156.2.312"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.FMJ05001X6"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vase Biol. 2000;20:1595–1599.","DOI":"10.1161\/01.ATV.20.6.1595"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vase Biol. 2003;23:85–89.","DOI":"10.1161\/01.ATV.0000048856.22331.50"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Baratta R, Amato S, Degano C, Farina MG, Patane G, Vigneri R, et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab. 2004;89:2665–2671.","DOI":"10.1210\/jc.2003-031777"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Cooper GD, Pickavance LC, Wilding JP, Halford JC, Goudie AJ. A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl). 2005;181:80–89.","DOI":"10.1007\/s00213-005-2224-4"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Ahima RS. Metabolic actions of adipocyte hormones: focus on adiponectin. Obesity. 2006;14 Suppl 1:9S–15S.","DOI":"10.1038\/oby.2006.276"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Baptista T, Beaulieu S. Are leptine and cytokines involved in body weight gain during treatment with antipsychotic drugs? Can J Psychiatry. 2002;47:742–749.","DOI":"10.1177\/070674370204700805"},{"key":"47","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00274.2003"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796–1808.","DOI":"10.1172\/JCI200319246"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821–1830.","DOI":"10.1172\/JCI200319451"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MBP. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacology. 2006;6:903–907.","DOI":"10.1016\/j.intimp.2005.12.007"},{"issue":"2","key":"51","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/intimm\/dxg027","volume":"15","author":"CLOEEZ-TAYARANI I","year":"2003","ISSN":"http:\/\/id.crossref.org\/issn\/0953-8178","issn-type":"print"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T12:47:11Z","timestamp":1683636431000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/jphs\/102\/2\/102_2_213\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.fp0060673","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"value":"1347-8613","type":"print"},{"value":"1347-8648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006]]}}}